Neuropace, Inc. is classed by the SEC under Surgical & Medical Instruments & Apparatus (industry code 3841), based in Mountain View, CA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $100 million and a loss of $21 million (its filed statements).
Product businessSurgical & Medical Instruments & ApparatusMountain View, CAfilings since 20118 of 9 filed, 1 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3841, Surgical & Medical Instruments & Apparatus); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 5.7 out of ten, 8 of 9 metrics filed and 1 estimated: past 6.3 out of ten, present 5.2 out of ten, future 5.7 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 8.3 out of ten. No warning events in its filings since 2017. 83rd percentile among 121 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 6.3 out of ten. +19.4% a year over 6 filed years; profitable in 0 of 6. 63rd percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 3.5 out of ten. CrossAssetData estimate 3.5/10, confidence 35 of 100 (one part). 35th percentile among 119 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 4.5 out of ten. ROE -113%: lost 113¢ per shareholder dollar. Leverage 82%: owes 82¢ per asset dollar. 45th percentile among 120 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 6.0 out of ten. top 40% of 109 in its family; net margin -21.5%. 60th percentile among 109 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 5.4 out of ten. top 46% of 90 in its family for leadership; chief executive since 2023. 54th percentile among 90 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 5.1 out of ten. top 49% of 104 in its family for room to expand. 51st percentile among 104 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 6.2 out of ten. top 38% of 105 in its family for growth drivers. 62nd percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 6.1 out of ten. top 39% of 88 in its family for expectations against reality. 61st percentile among 88 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-03-03 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-11 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-11 (on EDGAR). Newest filing: Form 4, 2026-09-25. Filings on record since 2011. Read from EDGAR 2026-10-12.
Who runs it
Becker, Joel (CHIEF EXECUTIVE OFFICER); Williams, Patrick F. (Chief Financial Officer); Morrell, Martha (CHIEF MEDICAL OFFICER); Fischer, Frank M (director); Geiger, Uri (director); Kumar, Rakhi (director); Andrade, Lisa (director); Huennekens, R Scott (director); Ryan, Renee (director); Lacob, Joseph (director). 10 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.